Claversal en es it fr

Claversal Brand names, Claversal Analogs

Claversal Brand Names Mixture

  • No information avaliable

Claversal Chemical_Formula


Claversal RX_link

No information avaliable

Claversal fda sheet

Claversal FDA

Claversal msds (material safety sheet)

Claversal Synthesis Reference

No information avaliable

Claversal Molecular Weight

145.156 g/mol

Claversal Melting Point

No information avaliable

Claversal H2O Solubility

Freely soluble

Claversal State


Claversal LogP


Claversal Dosage Forms

Cream for topical administration (160 mg/g of methyl aminolevulinate equivalent to 16.0% of methyl aminolevulinate)

Claversal Indication

For topical use, in combination with 570 to 670 nm wavelength red light illumination, in the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette).

Claversal Pharmacology

After topical application of methyl aminolevulinate, porphyrins will accumulate intracellularly in the treated skin lesions. The intracellular porphyrins (including PpIX) are photoactive, fluorescing compounds and, upon light activation in the presence of oxygen, singlet oxygen is formed which causes damage to cellular compartments, in particular the mitochondria. Light activation of accumulated porphyrins leads to a photochemical reaction and thereby phototoxicity to the light-exposed target cells.

Claversal Absorption

In vitro, after 24 hours the mean cumulative absorption through human skin was 0.26% of the administered dose.

Claversal side effects and Toxicity

The severity of local phototoxic reactions such as erythema, pain and burning sensation may increase in case of prolonged application time or very high light intensity.

Claversal Patient Information

Claversal Organisms Affected

Humans and other mammals